Screener
Iovance Biotherapeutics, Inc. IOVA Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
FAQ
- What is Iovance Biotherapeutics, Inc.'s total liabilities?
- Iovance Biotherapeutics, Inc. (IOVA) reported total liabilities of $179.49M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s total liabilities changed year-over-year?
- Iovance Biotherapeutics, Inc.'s total liabilities decreased by 14.1% year-over-year, from $208.95M to $179.49M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s total liabilities has grown at a 13.9% compound annual growth rate (CAGR), from $111.96M to $214.59M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Iovance Biotherapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude